{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T10:08:44Z","timestamp":1791540524292,"version":"4.3.4"},"reference-count":58,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T00:00:00Z","timestamp":1692489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Bia\u0142ystok\u2019s own funds"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>The use of 18F-PSMA-1007 and the role of PET\/MR in the diagnosis of prostate cancer are not conclusively confirmed. There are reports indicating the potential pros and cons of using 18F-PSMA-1007 as well as the PET\/MR technique in prostate cancer recurrence, but they are not yet included in the EAU guidelines. The aim of the study was to assess the effectiveness of 18F-PSMA-1007 PET\/MR in detecting BCR lesions at very low PSA levels &lt;0.5 ng\/mL. Methods: Sixty patients with BCR after radical prostatectomy (RP) with PSA ranged 0.1\u20130.5 ng\/mL were enrolled in a prospective study. All patients underwent simultaneous whole-body and pelvic 18F-PSMA-1007 PET\/MR. The obtained results were verified by 12-month follow-up. Results: Fifty-three lesions were detected in 45 patients with 75% detection rate. The mean PSA value was 0.31 ng\/mL. Of all PSMA-positive foci, 91% were localized in the pelvis, and only 9% of lesions were located in the extrapelvic region. Local recurrences were detected in 29%, PSMA-positive lymph nodes were detected in 64% of patients and bone metastases lesions were detected in 7% of patients. Conclusions: 18F-PSMA-1007 PET\/MR seems to be an excellent diagnostic tool in patients with early BCR with very low PSA levels, especially with dt PSA &lt; 6 months. The synergistic effect of combining 18F-PSMA-1007 and whole-body PET\/MR with precise multiparametric assessment of pelvic lesions is of particular benefit in early BCR.<\/jats:p>","DOI":"10.3390\/cancers15164185","type":"journal-article","created":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T01:46:56Z","timestamp":1692582416000},"page":"4185","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Application of 18F-PSMA-1007 PET\/MR Imaging in Early Biochemical Recurrence of Prostate Cancer: Results of a Prospective Study of 60 Patients with Very Low PSA Levels \u2264 0.5 ng\/mL"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1812-7275","authenticated-orcid":false,"given":"Ma\u0142gorzata","family":"Mojsak","sequence":"first","affiliation":[{"name":"Independent Laboratory of Molecular Imaging, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Szumowski","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Amelian","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Molecular Imaging, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Hladunski","sequence":"additional","affiliation":[{"name":"Independent Laboratory of Molecular Imaging, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo\u017cena","family":"Kubas","sequence":"additional","affiliation":[{"name":"Department of Radiology, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janusz","family":"My\u015bliwiec","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Kochanowicz","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Moniuszko","sequence":"additional","affiliation":[{"name":"Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15-276 Bialystok, Poland"},{"name":"Clinical Department of Allergic and Internal Diseases, Medical University of Bialystok, 15-276 Bialystok, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2015.04.023","article-title":"Survivorship and improving quality of life in men with prostate cancer","volume":"68","author":"Bourke","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer\u20142020 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II\u20142020 Update: Treatment of Relapsing and Metastatic Prostate Cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.juro.2017.02.070","article-title":"Oncologic and Functional Outcomes after Radical Prostatectomy for High or Very High Risk Prostate Cancer: European Validation of the Current NCCN\u00ae Guideline","volume":"198","author":"Pompe","year":"2017","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Artigas, C., Diamand, R., Shagera, Q.A., Plouznikoff, N., Fokoue, F., Otte, F.X., Gil, T., Peltier, A., Van Gestel, D., and Flamen, P. (2021). Oligometastatic Disease Detection with 68Ga-PSMA-11 PET\/CT in Hormone-Sensitive Prostate Cancer Patients (HSPC) with Biochemical Recurrence after Radical Prostatectomy: Predictive Factors and Clinical Impact. Cancers, 13.","DOI":"10.3390\/cancers13194982"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.eururo.2013.08.013","article-title":"Early salvage radiotherapy following radical prostatectomy","volume":"65","author":"Pfister","year":"2014","journal-title":"Eur. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved Metastasis-Free and Survival Outcomes with Early Salvage Radiotherapy in Men with Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer","volume":"34","author":"Stish","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40644-020-00373-4","article-title":"Detecting recurrent prostate cancer using multiparametric MRI, influence of PSA and Gleason grade","volume":"21","author":"Venkatesan","year":"2021","journal-title":"Cancer Imaging"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00259-016-3428-z","article-title":"(11)C-Choline PET\/CT for restaging prostate cancer. Results from 4,426 scans in a single-centre patient series","volume":"43","author":"Graziani","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/(SICI)1097-0045(19970701)32:2<140::AID-PROS9>3.0.CO;2-Q","article-title":"Prostate-specific membrane antigen","volume":"32","author":"Fair","year":"1997","journal-title":"Prostate"},{"key":"ref_12","first-page":"81","article-title":"Prostate-specific membrane antigen expression in normal and malignant human tissues","volume":"3","author":"Silver","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1073\/pnas.1735443100","article-title":"The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy","volume":"100","author":"Varlamova","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","article-title":"PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: Biodistribution in humans and first evaluation of tumour lesions","volume":"40","author":"Malcher","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s00259-014-2949-6","article-title":"The diagnostic value of PET\/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer","volume":"42","author":"Avtzi","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"668","DOI":"10.2967\/jnumed.115.154153","article-title":"Evaluation of Hybrid \u2076\u2078Ga-PSMA Ligand PET\/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy","volume":"56","author":"Eiber","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: A prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s11307-015-0844-6","article-title":"Radiofluorination of PSMA-HBED via Al(18)F(2+) Chelation and Biological Evaluations In Vitro","volume":"17","author":"Malik","year":"2015","journal-title":"Mol. Imaging Biol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2967\/jnumed.116.181768","article-title":"Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging","volume":"58","author":"Cardinale","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/s00259-016-3573-4","article-title":"F-18 labelled PSMA-1007: Biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients","volume":"44","author":"Giesel","year":"2017","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Hoffmann, M.A., von Eyben, F.E., Fischer, N., Rosar, F., M\u00fcller-H\u00fcbenthal, J., Buchholz, H.G., Wieler, H.J., and Schreckenberger, M. (2022). Comparison of [18F]PSMA-1007 with [68Ga]Ga-PSMA-11 PET\/CT in Restaging of Prostate Cancer Patients with PSA Relapse. Cancers, 14.","DOI":"10.3390\/cancers14061479"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Maisto, C., Aurilio, M., Morisco, A., de Marino, R., Buonanno Recchimuzzo, M.J., Carideo, L., D\u2019Ambrosio, L., Di Gennaro, F., Esposito, A., and Gaballo, P. (2022). Analysis of Pros and Cons in Using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007: Production, Costs, and PET\/CT Applications in Patients with Prostate Cancer. Molecules, 27.","DOI":"10.3390\/molecules27123862"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1007\/s00259-018-3952-0","article-title":"Advantage of 18F-PSMA-1007 over 68Ga-PSMA-11 PET imaging for differentiation of local recurrence vs. urinary tracer excretion","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00259-018-3989-0","article-title":"18F-PSMA-1007 PET\/CT at 60 and 120 minutes in patients with prostate cancer: Biodistribution, tumour detection and activity kinetics","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4495","DOI":"10.1007\/s00259-021-05456-3","article-title":"Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: A retrospective evaluation","volume":"48","author":"Arnfield","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","article-title":"Focal unspecific bone uptake on [18F]-PSMA-1007 PET: A multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging","volume":"48","author":"Maurer","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.urology.2019.04.004","article-title":"The Impact of 68Ga-PSMA PET\/CT and PET\/MRI on the Management of Prostate Cancer","volume":"130","author":"Hoffmann","year":"2019","journal-title":"Urology"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s11307-019-01424-4","article-title":"Whole-Body Integrated [68Ga]PSMA-11-PET\/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET\/CT as the Standard of Reference","volume":"22","author":"Guberina","year":"2020","journal-title":"Mol. Imaging Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1097\/01.ju.0000097124.21878.6b","article-title":"Can prostate specific antigen derivatives and pathological parameters predict significant change in expectant management criteria for prostate cancer?","volume":"170","author":"Khan","year":"2003","journal-title":"J. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41181-020-00101-0","article-title":"Automated [18F]PSMA-1007 production by a single use cassette-type synthesizer for clinical examination","volume":"5","author":"Naka","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: The EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","article-title":"PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies","volume":"73","author":"Rowe","year":"2018","journal-title":"Eur. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1007\/s00259-012-2069-0","article-title":"[68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: Comparison with 18F-FECH","volume":"39","author":"Haberkorn","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.2967\/jnumed.115.160382","article-title":"Prospective Comparison of 18F-Fluoromethylcholine Versus 68Ga-PSMA PET\/CT in Prostate Cancer Patients Who Have Rising PSA After Curative Treatment and Are Being Considered for Targeted Therapy","volume":"56","author":"Morigi","year":"2015","journal-title":"J. Nucl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1007\/s00256-019-03230-z","article-title":"Comparison of PSMA-PET\/CT, choline-PET\/CT, NaF-PET\/CT, MRI, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: A systematic review and meta-analysis","volume":"48","author":"Zhou","year":"2019","journal-title":"Skeletal radiology"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/RLU.0000000000001197","article-title":"68Ga-PSMA-PET\/CT in Patients with Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET\/CT","volume":"41","author":"Bluemel","year":"2016","journal-title":"Clin. Nucl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00259-015-3106-6","article-title":"PSMA PET\/CT with Glu-urea-Lys-(Ahx)-[\u2076\u2078Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer","volume":"42","author":"Giesel","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1756287218815793","DOI":"10.1177\/1756287218815793","article-title":"Detection rates of recurrent prostate cancer: 68Gallium (Ga)-labelled prostate-specific membrane antigen versus choline PET\/CT scans. A systematic review","volume":"11","author":"Moghul","year":"2019","journal-title":"Ther. Adv. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1007\/s00259-014-2872-x","article-title":"Impact of 11C-choline PET\/CT on clinical decision making in recurrent prostate cancer: Results from a retrospective two-centre trial","volume":"41","author":"Ceci","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s00259-015-3015-8","article-title":"[\u00b9\u00b9C]Choline PET\/CT predicts survival in hormone-naive prostate cancer patients with biochemical failure after radical prostatectomy","volume":"42","author":"Giovacchini","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1007\/s00259-015-3078-6","article-title":"(68)Ga-PSMA PET\/CT for restaging recurrent prostate cancer: Which factors are associated with PET\/CT detection rate?","volume":"42","author":"Ceci","year":"2015","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.eururo.2016.06.021","article-title":"Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis","volume":"70","author":"Perera","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection Efficacy of 18F-PSMA-1007 PET\/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00259-018-4089-x","article-title":"Diagnostic performance of 18F-PSMA-1007 PET\/CT in patients with biochemical recurrent prostate cancer","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s12149-021-01602-x","article-title":"High detection rate in [18F]PSMA-1007 PET: Interim results focusing on biochemical recurrence in prostate cancer patients","volume":"35","author":"Watabe","year":"2021","journal-title":"Ann. Nucl. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2967\/jnumed.119.229187","article-title":"Comparison of 68Ga-PSMA-11 PET\/CT and 18F-PSMA-1007 PET\/CT: Frequency of Pitfalls and Detection Efficacy in Biochemical Recurrence After Radical Prostatectomy","volume":"61","author":"Rauscher","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Treglia, G., Annunziata, S., Pizzuto, D.A., Giovanella, L., Prior, J.O., and Ceriani, L. (2019). Detection Rate of 18F-Labeled PSMA PET\/CT in Biochemical Recurrent Prostate Cancer: A Systematic Review and a Meta-Analysis. Cancers, 11.","DOI":"10.3390\/cancers11050710"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00259-018-4066-4","article-title":"68Ga-PSMA-11 PET\/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy and PSA < 0.5 ng\/mL. Efficacy and impact on treatment strategy","volume":"46","author":"Farolfi","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s00330-021-08140-0","article-title":"Prospective comparison of simultaneous [68Ga]Ga-PSMA-11 PET\/MR versus PET\/CT in patients with biochemically recurrent prostate cancer","volume":"32","author":"Jentjens","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"194","DOI":"10.2967\/jnumed.118.225276","article-title":"Detection Rate and Localization of Prostate Cancer Recurrence Using 68Ga-PSMA-11 PET\/MRI in Patients with Low PSA Values \u2264 0.5 ng\/mL","volume":"61","author":"Becker","year":"2020","journal-title":"J. Nucl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s00259-017-3850-x","article-title":"Clinical performance of 68Ga-PSMA-11 PET\/MRI for the detection of recurrent prostate cancer following radical prostatectomy","volume":"45","author":"Nagel","year":"2018","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s00259-013-2660-z","article-title":"Comparison of PET\/CT and PET\/MRI hybrid systems using a 68Ga-labelled PSMA ligand for the diagnosis of recurrent prostate cancer: Initial experience","volume":"41","author":"Haberkorn","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","article-title":"A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer","volume":"2","author":"Standaert","year":"2019","journal-title":"Eur. Urol. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1007\/s00345-019-02652-7","article-title":"A systematic review of contemporary management of oligometastatic prostate cancer: Fighting a challenge or tilting at windmills?","volume":"37","author":"Slaoui","year":"2019","journal-title":"World J. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Hammes, J., Hohberg, M., T\u00e4ger, P., Wild, M., Zlatopolskiy, B., Krapf, P., Neumaier, B., Schom\u00e4cker, K., Kobe, C., and Schmidt, M. (2018). Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET\/CT. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0209613"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s00259-019-04308-5","article-title":"Prospective comparison of whole-body MRI and 68Ga-PSMA PET\/CT for the detection of biochemical recurrence of prostate cancer after radical prostatectomy","volume":"46","author":"Sawicki","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4185\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:38:05Z","timestamp":1760128685000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4185"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,20]]},"references-count":58,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15164185"],"URL":"https:\/\/doi.org\/10.3390\/cancers15164185","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,20]]}}}